GLP-1 Receptor Agonists vs. Basal Insulin: HbA1c and Cardiovascular Outcomes in Type 2 Diabetes
Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin
Abstract
GLP-1 receptor agonists are compared against basal insulin in type 2 diabetes patients, evaluating HbA1c and cardiovascular outcomes.